Clinical Application of Blood Lactate, C‐Reactive Protein, and the Age‐Adjusted Charlson Comorbidity Index in Predictive Assessment of Malignant Risk of MRSA Pneumonia
Abstract
Background The objective of this study is to develop an early warning model that combines the age‐adjusted Charlson comorbidity index (aCCI) with serum lactate (Lac) and C‐reactive protein (CRP) levels to predict the progression of early methicillin‐resistant Staphylococcus aureus (MRSA) pneumonia into severe pneumonia (SP). Methods This study was a retrospective case–control analysis. Sixty‐four inpatients diagnosed with MRSA pneumonia at the First Affiliated Hospital of Soochow University from November 2023 to August 2024 were selected as study subjects. They were divided into two groups: the SP group (SP group) and the non‐SP (nSP) group, based on established diagnostic criteria for SP. Demographic, clinical, and laboratory data of the patients were collected and statistically analyzed. Results Twenty‐four patients (37.5%) developed SP, and the aCCI score was significantly higher in the SP group compared to the nSP group, with a statistically significant difference between the two groups (p 0.05). The levels of CRP and serum Lac in the SP group were significantly higher than those in the nSP group, with statistically significant differences (p < 0.05). Multifactorial logistic regression analysis indicated that HA‐MRSA was an independent protective factor against MRSA‐associated SP, while the aCCI score, CRP, and serum Lac levels were identified as risk factors for the progression of MRSA to SP. The combination of these three factors demonstrated good predictive efficacy,…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.